A clinical audit of antithrombin concentrate use in a tertiary paediatric centre
Journal of Paediatrics and Child Health,

Kozul C et al. – This data provides the basis for future investigations of the specific biochemical changes accompanying antithrombin concentrate (ATC) administration and the development of paediatric–specific evidence–based guidelines for ATC use.

Methods
  • A clinical audit was performed of patients treated with ATC during two 12-month periods: 1 June 1999–1 June 2000 and 1 June 2009–1 June 2010.

Results
  • Thirty-seven patients whose age ranged from 1 day to 13.5 years (median 30 days) received a median of two doses (range 1–15) with a median dose of 40 units/kg (range 1–200 units).
  • The majority (90%) of patients were located in the intensive care unit, and the major indication (76%) for use of the ATC was in the setting of unfractionated heparin (UFH) resistance.
  • Post-ATC administration, 32% of the doses given resulted in antithrombin levels reaching age-specific normative levels.
  • Of the patients administered ATC with the aim of optimising UFH therapy, 28% of patients had their UFH dose reduced without any measurement of UFH effect.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Family Medicine

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Family Medicine Articles

Indexed Journals in Family Medicine: American Family Physician, Archives of Family Med, Annals of Family Medmore